ArticleThe Permanente journal2015
Elderly patients with glioblastoma multiforme treated with concurrent temozolomide and standard- versus abbreviated-course radiotherapy.
Article in The Permanente journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 4 syntheses or guidelines pooled it, 25 citations in OpenAlex.
- Pooled it
- Survival after hypofractionation in glioblastoma: a systematic review and meta-analysis.Radiation oncology (London, England) · 2020Pooled it
- Hypofractionated versus standard radiation therapy in combination with temozolomide for glioblastoma in the elderly: a meta-analysis.Journal of neuro-oncology · 2019Pooled it
- Management of elderly patients with glioblastoma-multiforme-a systematic review.The British journal of radiology · 2018Pooled it
- Exploring management and outcomes of elderly patients with glioblastoma using data from two randomised trials (GEINO1401/EX-TEM).Journal of neuro-oncology · 2024Trial
- Patterns of failure in glioblastoma multiforme following Standard (60 Gy) or Short course (40 Gy) radiation and concurrent temozolomide.Japanese journal of radiology · 2023Article
- Standard 6-week chemoradiation for elderly patients with newly diagnosed glioblastoma.Scientific reports · 2021Article
- Adjuvant Radiation in Older Patients With Glioblastoma: A Retrospective Single Institution Analysis.Frontiers in oncology · 2021Article
- Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.Radiation oncology (London, England) · 2019Article
- Glioblastoma Multiforme in the over 70's: "To treat or not to treat with radiotherapy?"Cancer medicine · 2019Article
- Survival in elderly glioblastoma patients treated with bevacizumab-based regimens in the United States.Neuro-oncology practice · 2018Article
- Impact of standard care on elderly glioblastoma patients.Neuro-oncology practice · 2017Article
- Feasibility evaluation of hypofractionated radiotherapy with concurrent temozolomide in elderly patients with glioblastoma.International journal of clinical oncology · 2016Article
- Age alone is not a predictor for survival in glioblastoma.Journal of neuro-oncology · 2016Article
- Glioblastoma in the elderly: Therapeutic dilemmas.Surgical neurology international · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextGlioblastoma multiforme (GBM) is an aggressive neoplasm, with controversy regarding treatment in elderly patients.
objectiveTo review outcomes of elderly patients aged ≥ 65 with newly diagnosed GBM treated with concurrent temozolomide and either standard-course radiotherapy (SRT) or abbreviated-course radiotherapy (ART).
designRetrospective review from 2003 to 2012.
main outcome measureSurvival, comparing treatment regimens. One hundred patients received SRT (median dose = 60 Gy), and 29 received ART (median dose = 35 Gy). O6- methylguanine-DNA methyltransferase (MGMT) status was available for 26 SRT and 13 ART recipients.
resultsMedian age was 70 years. Median follow-up was 11 months. At analysis, 3 patients were alive. Multivariate analysis of the entire cohort found SRT (hazard ratio [HR] = 0.421, p = 0.0001), Karnofsky Performance Score of 70 or higher (HR = 1.894, p = 0.0031), and more extensive surgery (HR = 0.466, p = 0.0023) were associated with longer survival time, but age was not. Median time to death with SRT was 13 months versus 5.4 months with ART, but the latter had worse prognostic factors, including lower Karnofsky Performance Scores, fewer gross total resections, and higher recursive partitioning analysis class. Recipients of SRT with methylated MGMT promoter had a trend toward longer survival compared with unmethylated MGMT (p = 0.06), but ART recipients had shorter survival with MGMT methylation (p = 0.02).
conclusionElderly patients with multiple poor prognostic factors given ART had short survival times. Relative to other variables, MGMT status may not predict outcome for these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.